Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $19.3252W HIGH $30.96
Volume
2.01 M
Value Traded
79.95 M
Short % Float
5.69%
-1.85%Week
-29.26%1 Month
-25.32%3 Month
-9.94%6 Month
-4.09%5 Year
+183.6%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.37 B
EPS (TTM)
2.21
P/E Ratio
8.87
Ent. Value
2.42 B
Total Shares
172.32 M
Float Shares
170.04 M
Insiders
1.31%
Institutions
97.83%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ACAD Catalyst Timeline
Dated clinical, regulatory and corporate events for ACADIA Pharmaceuticals Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for ACADIA Pharmaceuticals Inc.
378Total events
12Upcoming
112Tier-1 (high impact)
2010 to 2041Coverage
Upcoming catalysts 2
Event history 50
▲Patent GrantedTrofinetideApprovedIP / Competition
USPTO issues Notice of Allowance for U.S. Patent Application No. 17/590,496 covering weight-banded dosing of trofinetide
Rett syndromesource ↗
◆Topline ReadoutremlifanserinClinical Data
Acadia announces Phase 3 enabling topline results from Phase 2 RADIANT study of remlifanserin in ADP
Alzheimer's disease psychosis (ADP)source ↗
▼Primary Endpoint MissedremlifanserinClinical Data
Remlifanserin 60 mg narrowly misses primary endpoint of SAPS-H+D in Phase 2 RADIANT (p=0.0603)
Alzheimer's disease psychosis (ADP)source ↗
▲Secondary Endpoint DataremlifanserinClinical Data
Remlifanserin 60 mg achieves nominal significance on key secondary endpoint CGI-S-ADP (p=0.0077)
Alzheimer's disease psychosis (ADP)source ↗
▲Safety Data UpdateremlifanserinClinical Data
Remlifanserin demonstrates favorable safety profile in Phase 2 RADIANT with no QT signal, no motor/cognition impact, no deaths
Alzheimer's disease psychosis (ADP)source ↗
◆Topline ReadoutremlifanserinClinical Data
Topline Phase 2 results from RADIANT program expected
Alzheimer's disease psychosissource ↗
▲EU ApprovalTrofinetideApprovedEx-US Regulatory
La Commissione europea approva DAYBU (trofinetide) per la sindrome di Rett
sindrome di Rettsource ↗
●R&D DayPresentation
Acadia to participate in fireside chat at Canaccord Genuity 46th Annual Growth Conference
▲Fast Track DesignationremlifanserinDesignation
FDA Fast Track designation for remlifanserin in Alzheimer's disease psychosis
Alzheimer's disease psychosissource ↗
▲Enrollment CompleteremlifanserinTrial
RADIANT Phase 2 enrollment completed
Alzheimer's disease psychosissource ↗
▲Trial InitiationremlifanserinTrial
Phase 3 screening and enrollment underway
Alzheimer's disease psychosissource ↗
◆Topline ReadoutremlifanserinClinical Data
Top-line results from Phase 2 RADIANT study expected
Alzheimer's disease psychosissource ↗
▲CHMP Positive OpinionTrofinetideApprovedEx-US Regulatory
CHMP positive opinion for DAYBU (Trofinetide) in EU
Rett-Syndromsource ↗
▲CHMP Positive OpiniontrofinetydEx-US Regulatory
CHMP positive opinion for trofinetyd in Rett syndrome
Rett syndromesource ↗
▲CHMP Positive OpinionTrofinetideApprovedEx-US Regulatory
CHMP positive opinion for DAYBU (trofinetide) in Rett syndrome
Rett syndromesource ↗
▲CHMP Positive OpiniontrofinétideEx-US Regulatory
CHMP positive opinion for DAYBU (trofinétide) in Rett syndrome
syndrome de Rettsource ↗
▲CHMP Positive OpinionTrofinetideApprovedEx-US Regulatory
CHMP positive opinion for DAYBU (trofinetide) in EU
Rett syndromesource ↗
◆Topline ReadoutACP-204Clinical Data
Topline results for RADIANT Phase 2 study of ACP-204
Alzheimer's disease psychosissource ↗
◆Oral PresentationPresentation
2026 RBC Capital Markets Global Healthcare Conference Fireside Chat
▲Product LaunchPost-Market
DAYBUE STIX (trofinetide) broadly available in the US for Rett Syndrome
Rett Syndromesource ↗
▲Product LaunchPost-Market
Full launch of DAYBUE STIX powder formulation expected in early Q2 2026
Rett syndromesource ↗
◆Oral PresentationPresentation
Acadia Pharmaceuticals to participate in fireside chat at Stifel 2026 Virtual CNS Forum
▼CHMP Negative OpinionTrofinetideApprovedEx-US Regulatory
CHMP adopted negative opinion for trofinetide MAA
Rett syndromesource ↗
▼CHMP Negative OpinionTrofinetideApprovedEx-US Regulatory
CHMP negative trend vote on MAA for trofinetide in Rett syndrome
Rett syndromesource ↗
●Oral PresentationPresentation
Acadia Pharmaceuticals presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Product LaunchPost-Market
U.S. launch of DAYBUE STIX on a limited basis begins Q1 2026
Rett syndromesource ↗
◆Timing GuidanceACP-101Presentation
NDA submission planned for Q1 2026 if topline results positive
Prader Willi Syndromesource ↗
◆EU ApprovalTrofinetideApprovedEx-US Regulatory
Expected EMA approval for trofinetide
Rett syndromesource ↗
▲Enrollment CompleteACP-204Trial
Last patient enrollment expected for RADIANT Phase 2 study of ACP-204
Alzheimer's disease psychosissource ↗
▲Trial InitiationACP-204Trial
Initiation of Phase 2 study of ACP-204 for Lewy Body Dementia Psychosis
Lewy Body Dementia Psychosissource ↗
▲Trial InitiationTrofinetideApprovedTrial
Initiation of Phase 3 trial of trofinetide for Rett syndrome in Japan
Rett syndromesource ↗
▲Quarterly UpdateNUPLAZIDApprovedCorporate
NUPLAZID net product sales guidance narrowed and raised to $685-$695 million
Parkinson's disease psychosissource ↗
▲Quarterly UpdateDAYBUEApprovedCorporate
DAYBUE net product sales guidance updated to $385-$400 million
Rett syndromesource ↗
◆Topline ReadoutACP-101Clinical Data
Topline results from COMPASS PWS Phase 3 study expected early Q4 2025
Prader Willi Syndromesource ↗
▲Enrollment CompleteACP-101Trial
Last patient enrollment expected for COMPASS PWS Phase 3 study of ACP-101
Prader-Willi Syndromesource ↗
▲IP Litigation RulingNUPLAZIDApprovedIP / Competition
Patent litigation wins securing market exclusivity for NUPLAZID; composition-of-matter patent expiry 2030, formulation patent expiry 2038
Parkinson's disease psychosissource ↗
●Management ChangeCorporate
Appointed Allyson McMillan-Youngblood as SVP, Rare Disease Franchise
▲Other Regulator MilestoneTrofinetideApprovedEx-US Regulatory
Commenced named patient supply of trofinetide in Europe, Israel, and select rest of world
Rett syndromesource ↗
●Trial InitiationACP-204Trial
Initiation of Phase 2 study of ACP-204 for Lewy Body Dementia Psychosis
Lewy Body Dementia Psychosissource ↗
Past FDA Catalysts and PDUFA Decisions
How ACAD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-06-30 | ACP-101 | Phase 3 topline data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C49 / 100
Pipeline Score
$406M
Pipeline Value
$5.0B
Commercial Value
Undervalued
Valuation Signal
6
Drugs Scored
0.4x
rNPV / MCap
Top 18%
Small Cap(rank 119 of 658)
Percentile Rank
ACADIA Pharmaceuticals Inc. carries a moderate pipeline score (49/100), with $624M risk-adjusted pipeline value, led by ACP-211 in Major Depressive Disorder (MDD) (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $1.1B x 4.4 = $5.0B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| NUPLAZID | $702M | $650M | +7.9% |
| Daybue | $437M | $369M | +18.5% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ACP-211 Small moleculeNCT07284667 | Major Depressive Disorder (MDD) | Phase 2 | RECRUITING | 153 | Sep 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every ACAD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Remlifanserin Fast Track | Alzheimer’s Disease Psychosis | Phase 2 | 2026-09-24 | favorable outcome for the 60 mg dosageRead More | Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Schneyer Mark C.Officer (EVP, CHIEF FINANCIAL OFFICER) | Option | 14,292 82,120 held | $17.84 | 08/06/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ACAD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 5.4 % (-1.8 %) | 1.09 B | 42.91 M | 0.04% ( 16.21 K) |
ACAD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-03-19 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ACAD ranks across every disease it competes in
Competitive Position is a premium feature
See how ACAD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialACAD News
ACADAcadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041
Acadia Pharmaceuticals has received a Notice of Allowance from the USPTO for its U.S. Patent Application No. 17/590,496, which covers weight-banded dosing of Trofinetide for treating Rett Syndrome. This patent is expected to be issued soon, extending protections until March 2041. This development enhances the company's market position and potential revenue from Trofinetide.
Read more →ACAD▼ -12.8%on this newsshared move
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP)
Acadia Pharmaceuticals has reported positive topline results from the Phase 2 segment of the RADIANT study, which evaluates remlifanserin for treating hallucinations and delusions in Alzheimer's disease psychosis. The primary endpoint, assessing changes in symptoms, indicates a favorable outcome for the 60 mg dosage. This sets the stage for further Phase 3 trials.
Read more →ACADRiassunto: La Commissione europea approva DAYBU® (trofinetide) come primo e unico trattamento dei sintomi neuro-comportamentali della sindrome di Rett nell'Unione Europea
Acadia Pharmaceuticals has received European Commission approval for DAYBU (trofinetide) as the first and only treatment for neurobehavioral symptoms of Rett syndrome. This approval applies to patients aged five and older, marking a significant advancement in care for this condition. The approval is a major milestone for the company and those affected by Rett syndrome.
Read more →ACADDe Europese Commissie keurt DAYBU® (trofinetide) goed als eerste en enige behandeling voor neurologische gedragssymptomen van het Rett-syndroom in de Europese Unie
Acadia Pharmaceuticals has received approval from the European Commission for DAYBU (trofinetide), marking it as the first and only treatment for neurological behavioral symptoms of Rett syndrome in the European Union. This approval applies to both adult and pediatric patients aged five and older, representing a significant milestone in treatment options for this condition.
Read more →ACADEuropean Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Acadia Pharmaceuticals has received marketing authorization from the European Commission for DAYBU (trofinetide), the first treatment approved for neurobehavioral symptoms of Rett syndrome in the EU. This approval is a significant advancement for patients aged five years and older, providing a new therapeutic option for managing this condition.
Read more →ACAD▲ +6.1%on this news
Acadia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Acadia Pharmaceuticals reported a strong financial performance for the second quarter of 2026, with a 17% year-over-year revenue growth on an adjusted basis. The CEO highlighted the successful commercial execution of both DAYBUE and NUPLAZID, attributing the growth to increased patient demand and uptake of STIX. This positive trend indicates a robust market position for Acadia.
Read more →ACADAcadia Pharmaceuticals to Participate in the Canaccord Genuity 46th Annual Growth Conference
Acadia Pharmaceuticals Inc. has announced its participation in the Canaccord Genuity 46th Annual Growth Conference. The event is scheduled for August 12, 2026, at 1:30 p.m. Eastern Time. Investors can access live webcasts on the company's website, with recordings available for a month post-event.
Read more →ACADAcadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis
Acadia Pharmaceuticals has received Fast Track designation from the FDA for remlifanserin, aimed at treating hallucinations and delusions in Alzheimer's disease psychosis. This designation is intended to expedite the drug's development and review process, highlighting the urgency of addressing serious conditions like ADP. The investigational drug is a selective 5-HT2A receptor inverse agonist.
Read more →ACADAcadia Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 4, 2026
Acadia Pharmaceuticals Inc. will report its second quarter 2026 financial results on August 4, 2026, after U.S. market close. The management team will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day. This event will be accessible on Acadia's website and archived for 90 days.
Read more →ACADAcadia Pharmaceuticals Appoints Carl Segerstrom as Chief People Officer
Acadia Pharmaceuticals has appointed Carl Segerstrom as the new Chief People Officer. This leadership change aims to enhance the company's human resources strategy. The appointment reflects Acadia's commitment to fostering a strong organizational culture.
Read more →ACADDAYBU® (trofinetyd) zalecany w UE przez CHMP do stosowania w leczeniu zespołu Retta
The CHMP has recommended DAYBU® (trofinetyd) for use in the treatment of Rett syndrome in the EU. This recommendation marks a significant step forward in providing therapeutic options for patients suffering from this condition. The endorsement from the CHMP highlights the potential benefits of trofinetyd in managing Rett syndrome.
Read more →ACADDAYBU® (Trofinetide) vom CHMP für die Zulassung in der Europäischen Union empfohlen
The article discusses the recommendation by the CHMP for the approval of DAYBU® (Trofinetide) in the European Union. However, no specific details or implications regarding this recommendation are provided in the text.
Read more →ACADDAYBU® (trofinétide) recommandé dans l’UE par le CHMP pour le traitement du syndrome de Rett
The CHMP has recommended DAYBU® (trofinétide) for the treatment of Rett syndrome in the EU. This recommendation marks a significant advancement in addressing the needs of patients suffering from this rare neurological disorder. If approved, it could lead to improved treatment options for affected individuals.
Read more →ACADDAYBU® (trofinetide) in de EU aanbevolen door CHMP voor de behandeling van het Rett-syndroom
The CHMP has recommended DAYBU® (trofinetide) for the treatment of Rett syndrome in the EU. This recommendation is a significant step towards potential approval, but further details on the implications and next steps are not provided.
Read more →ACAD▲ +6.7%on this newsshared move
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP
The Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of DAYBU® (trofinetide) in the European Union. This recommendation marks a crucial advancement for the drug, which is aimed at addressing specific medical needs. The decision is now pending final approval from the European Commission.
Read more →ACADAcadia Pharmaceuticals Reports First Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance
Acadia Pharmaceuticals has released its financial results for the first quarter of 2026, reaffirming its financial guidance for the year. The report indicates the company's ongoing commitment to its financial targets despite the current market conditions. Further details on revenue and expenditures were not disclosed in the article.
Read more →ACADAcadia Pharmaceuticals Announces Planned Year-End Retirement of Elizabeth H.Z. Thompson, Ph.D., Head of Research and Development, Following a Distinguished Career
Acadia Pharmaceuticals announced the planned retirement of Dr. Elizabeth H.Z. Thompson, Head of Research and Development, for personal reasons. She will remain in her role until a successor is appointed and will continue as a consultant through at least 2026. Acadia is actively searching for a new R&D leader while maintaining its clinical development programs.
Read more →ACADAcadia Pharmaceuticals to Participate at Upcoming May 2026 Investor Conferences
Acadia Pharmaceuticals has announced its participation in two upcoming investor conferences in May 2026. The first is the BofA Securities 2026 Health Care Conference, and the second is the RBC Capital Markets Global Healthcare Conference. Live webcasts of the events will be available on the company's website, ensuring accessibility for investors.
Read more →ACADAcadia Pharmaceuticals to Participate at Upcoming Investor Conferences
Acadia Pharmaceuticals Inc. will participate in two upcoming investor conferences, including the BofA Securities 2026 Health Care Conference and the RBC Capital Markets Global Healthcare Conference. The presentations will be available via live webcasts on the company's website. Acadia focuses on developing treatments for neurological and rare diseases, with a strong pipeline of programs.
Read more →ACADAcadia Pharmaceuticals to Present Data at the 2026 American Academy of Neurology (AAN) Annual Meeting
Acadia Pharmaceuticals is set to present data at the upcoming 2026 American Academy of Neurology Annual Meeting. The details regarding the specific data to be presented are currently unspecified. This event is significant for the company as it showcases their ongoing research efforts in neurology.
Read more →About ACADIA Pharmaceuticals Inc.
Headquarters12830 EL CAMINO REAL, SAN DIEGO, CA, 92130
Founded1993
BIOPHARMAWATCH ELITE PLUS
Trade the next ACAD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime